Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

Lawsuit alleges Tenax Therapeutics, Inc. misled investors who acquired its securities from November 13, 2023 to August 7, 2026; lead plaintiff deadline is December 28, 2026

LOS ANGELES--(BUSINESS WIRE)--A securities class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities from November 13, 2023 to August 7, 2026, inclusive. The Law Offices of Frank R. Cruz today reported the case, Katz v. Tenax Therapeutics, Inc. et al., filed on October 26, 2026 in the U.S. District Court North Carolina Middle District (Case No. 1:26-cv-01264). Lead plaintiff motions in the Tenax Therapeutics, Inc. case are due by December 28, 2026.

If you lost money on Tenax Therapeutics, Inc. investments, contact The Law Offices of Frank R. Cruz to learn more about the Tenax Therapeutics, Inc. class action and your potential claims under the federal securities laws before the December 28, 2026 lead plaintiff deadline.

Tenax Therapeutics, Inc. lawsuit key dates

• Filed: October 26, 2026
• Court: U.S. District Court North Carolina Middle District
• Class period: November 13, 2023 to August 7, 2026, inclusive
• Lead plaintiff motion deadline: December 28, 2026

What happened?

On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."

On this news, Tenax's stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.

What is the Tenax Therapeutics, Inc. class action about?

The Tenax Therapeutics, Inc. securities lawsuit alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Tenax Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' positive statements about Tenax Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities during the class period may ask the Court, no later than December 28, 2026, to appoint them lead plaintiff in this putative class action.

"According to the complaint filed against Tenax Therapeutics, Inc., the Company, among other things, failed to disclose that TNX-103 was less effective than Defendants had led investors to believe. Now that the case has been filed, the December 28, 2026 deadline is the date investors who bought during the class period should know," said Frank R. Cruz of The Law Offices of Frank R. Cruz.

What should Tenax Therapeutics, Inc. investors do now?

The Law Offices of Frank R. Cruz can help Tenax Therapeutics, Inc. investors evaluate potential claims to recover their losses. To learn more, visit the Tenax Therapeutics, Inc. case page, email [e-mail], or call 310-914-5007.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

Tenax Therapeutics, Inc. investors need not take any action at this time to be class members. Investors may retain counsel of their choice or take no action and remain absent class members. No class has been certified yet in the Tenax Therapeutics, Inc. case.

Questions and answers about the Tenax Therapeutics, Inc. class action

Who is eligible? Investors who bought Tenax Therapeutics, Inc. securities between November 13, 2023 and August 7, 2026 and lost money may be class members in the Tenax Therapeutics, Inc. securities lawsuit.

What does a lead plaintiff do? The lead plaintiff is appointed by the court to represent all class members and direct the Tenax Therapeutics, Inc. class action, and lead plaintiff motions are due by December 28, 2026.

Must I act now to be part of the Tenax Therapeutics, Inc. class? No, Tenax Therapeutics, Inc. investors need not take any action at this time and may remain absent class members.

How are attorneys' fees handled? The Law Offices of Frank R. Cruz works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval.

About The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.

Prior results do not guarantee a similar outcome.

Related links

• Tenax Therapeutics, Inc. case page, The Law Offices of Frank R. Cruz
• Complaint: Katz v. Tenax Therapeutics, Inc. et al., U.S. District Court North Carolina Middle District
• Tenax Press Release
• Tenax Therapeutics, Inc. SEC filings index, EDGAR
• The Law Offices of Frank R. Cruz

Follow The Law Offices of Frank R. Cruz for updates on Twitter: twitter.com/FRC_LAW

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.